Self-Study 2024 Release I: Updates in Uveal Melanoma

Type: Individual•Format: On-demand

Uveal melanoma is rare, accounting for only 3-5% of all melanomas, but is the most common primary intraocular malignancy. Although recent advancements have improved treatment options, uveal melanoma is associated with high rates of metastases and mortality. The purpose of this course is to review treatment options and updates in the management of uveal melanoma. This will include a review of tebentafusp-tebn, its efficacy and safety data, and considerations for administration and toxicity management, as well as a review of immunotherapy in uveal melanoma.

Updates in Uveal Melanoma

UAN# 0465-0000-24-074-H01-P

Author: Christine Barrett, PharmD, BCOP

Learning Objectives

  1. Recall the differences in biology, prognosis, and treatment of uveal melanoma in comparison to cutaneous melanoma
  2. Review the safety and efficacy data for tebentafusp-tebn in metastatic uveal melanoma
  3. Describe treatment considerations for tebentafusp-tebn, including administration and toxicity management
  4. Identify the efficacy and safety data of immunotherapy in metastatic uveal melanoma

Get it

Knowledge Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.